Nice!!V.NU | November 6, 2017 NeutriSci Announces Pending Approval From Japanese Government for Distribution of CBD Products Through Naturally Splendid VANCOUVER, BC --(Marketwired - November 06, 2017) - NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX VENTURE: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9), the innovator and pioneer behind neuenergy, is pleased to announce that its partner in Japan and South Korea for Ambarii Corporation ("Ambarii") CBD products, Naturally Splendid USA ("Naturally Splendid"), expects final approval imminently from the Japanese government for distribution of CBD products in Japan. Naturally Splendid has contributed significant work towards the application process to launch CBD infused products into the Japanese market through an e-commerce campaign being managed by First Step Japan ("FSJ"). FSJ is a marketing and distribution company located in Tokyo with extensive expertise in the Japanese consumer market. Naturally Splendid's Japanese specific website for this market will be activated immediately upon final approval. Ambarii is a joint venture between NeutriSci and Lexaria Bioscience Corp. ("Lexaria") that was formed to produce and commercialize a line of healthy, sugar-free, edible cannabinoid quick dissolving tablets combining NeutriSci's proprietary pterostilbene tablet form factor and Lexaria's patented palatability and absorption enhancing technology. Mr. Glen Rehman, President of NeutriSci International, commented, "Naturally Splendid will be marketing Ambarii's proprietary mouth-melt full spectrum hemp CBD tablets in Japan and South Korea. Initial samples incorporating Naturally Splendid's HempOmega technology with Ambarii's fast-acting and highly absorbent delivery mechanism are in the process of being evaluated and tested and we look forward to commencing distribution in these new markets." Lexaria, a drug delivery platform innovator, recently announced it has received a new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for the use of its technology as a delivery platform for all cannabinoids including THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications ("NSAIDs"); and nicotine. Lexaria's technology in Ambarii products will be a significant differentiator for Japanese consumers looking for high quality products. Read more at https://www.stockhouse.com/news/press-releases/2017/11/06/neutrisci-announces-pending-approval-from-japanese-government-for-distribution#uWp5eMxXbWau8POO.99